Stepping up the fight to end HIV, TB and malaria among women and children

Total contribution
JPY 1.86 billion
Partner since

Millions of lives are lost worldwide every year due to AIDS, tuberculosis (TB) and malaria, constituting a major obstacle to growth in developing countries. Africa suffers from a particularly severe shortage of health care providers, which hinders the provision of health care services to overcome these three diseases.

Antenatal and postnatal care are suitable entry points for the critical expansion of disease prevention, screening and treatment. However, the delivery of the recommended interventions during antenatal care, including screening, diagnosis and management of infectious diseases, remains below global targets.

Partnering with Takeda

Takeda has supported the Global Fund since 2010, making it the longest corporate partnership to date and an exemplary model of private sector engagement. Its financial support has helped strengthen the capacity of health workers in Kenya, Nigeria and Tanzania, and build resilient and sustainable health systems, a key strategic objective of the Global Fund.

Takeda’s first pledge of JPY 1 billion (approximately US$10 million) for 2010-2019 helped boost malaria prevention efforts in Tanzania with the distribution of mosquito nets, accelerated access to TB treatment in Kenya and expanded HIV services and awareness in Nigeria.

In 2019, Takeda became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment, pledging an additional JPY 1 billion over five years. This investment supports the improvement of maternal and child health by integrating quality HIV, TB and malaria services in antenatal and postnatal care in several priority countries in Africa.

“Our commitment to Better Health and a Brighter Future extends beyond our work at the cutting edge of innovation to bold, long-term investments in disease prevention, capacity building, and access to healthcare in partnership with the global community. Supporting the Global Fund over the past 10 years has yielded results that are very important to us, and that is why we are proud to continue to partner with the Global Fund on the Takeda Initiative 2.”
Christophe Weber, President & CEO, Takeda Pharmaceutical Company